Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Willem Kuyken, from the University of Oxford Department of Psychiatry, leads the analysis into the efficacy of MBCT in prevention of depressive relapse.

The largest meta-analysis so far of Mindfulness-Based Cognitive Therapy (MBCT) for recurrent depression has found that MBCT is an effective treatment option that can help prevent the recurrence of major depression. The study used anonymised individual patient data from nine randomized trials of MBCT. It suggests that for the millions of people who suffer recurrent depression it provides a treatment choice and an alternative or addition to other approaches such as maintenance anti-depressants.

While MBCT is not a panacea, it does clearly offer those with a substantial history of depression a new approach to learning skills to stay well in the long-term. It offers people a safe and empowering treatment choice alongside other mainstay approaches such as cognitive-behavioural therapy and maintenance antidepressants.
- Willem Kuyken, Professor of Clinical Psychology and Director of the Oxford Mindfulness Centre

 

Major depression is a significant public health problem. Without ongoing treatment, as many as four out of five people with depression relapse at some point.  MBCT is a group-based psychological treatment that helps people change the way they think and feel about their experiences and learn skills that reduce the likelihood of further episodes of depression. This meta-analysis, included data from trials that compared MBCT to usual care as well as to other active treatments such as maintenance antidepressants – the current mainstay approach to prevention of depressive relapse.

 “This new evidence for Mindfulness-based Cognitive Therapy, collated from individual patient data across nine randomised trials is very heartening," says Professor Willem Kuyken. "We need to do more research, however, to get recovery rates closer to 100% and to help prevent the first onset of depression, earlier in life. These are programmes of work we are pursuing at the University of Oxford and with our collaborators around the world."

Across the nine trials, 38% of those who received MBCT had a depressive relapse within 60 weeks’ follow-up, in contrast to 49% of those who did not receive MBCT. Taking the time to relapse into account, people who received MBCT were 31% less likely to relapse during the 60-week follow-up compared with those who did not receive MBCT.

The inclusion of individual patient data made it possible to demonstrate that a person’s age, sex, level of education and the age at which they first became depressed did not significantly influence the effectiveness of MBCT, suggesting that this approach is useful for a broad range of people. Those people who experienced more symptoms of depression when they entered treatment tended to show greater benefits from MBCT compared with other treatments. Clinical trials systematically record the occurrence of adverse events and negative outcomes such as death or hospitalisation for any cause. The study found no evidence of adverse events associated with MBCT when delivered by well-trained teachers in a clinical context.

Four of the trials that contributed to the meta-analysis compared MBCT combined with continuation, tapering, or discontinuation of antidepressants to continued maintenance antidepressant treatment alone. Data from these trials showed that those who received MBCT, and in many cases tapered or discontinued antidepressant medication, were 23% less likely to relapse to major depression than those who continued on antidepressants and did not receive MBCT.

Read more about Oxford Mindfulness Centre 

Read the full paper, published in JAMA Psychiatry

Read the Editorial, analysing the paper in JAMA Psychiatry

 

Read how the study was reported in the media:

The Independent: ‘Mindfulness therapy works as well as anti-depressant drugs, major new study finds’ 

Huffington Post: ‘Mindfulness effective treatment for depression

The Daily Telegraph: ‘Mindfulness ‘can work as well as antidepressants’

The Daily Telegraph: Mindfulness works - which is why I'm implementing it at my university

The Guardian online: Has mindfulness helped improve your mental health? Share your story 

International Business Times UK online: ‘Mindfulness reduces risk of depression relapse and is just as effective as antidepressants’

CBC online: ‘Mindfulness therapy to prevent depression relapse 'on par' with drugs, review shows

Fox News (US): Mindfulness therapy works for recurrent depression

Reuters: Mindfulness therapy works for recurrent depression